Jiangsu Recbio Technology Reports P-II Study Results of Two-Component COVID-19 Vaccine ReCOV
- The P-II study evaluating the immunogenicity & safety profile of recombinant two-component COVID-19 vaccine ReCOV vs Pfizer's mRNA vaccine Comirnaty in patients with COVID-19 in the Philippines
- The results showed a superior neutralizing Ab titer level against Omicron BF.7 & BA.2.75 over mRNA vaccine, SCR of neutralizing Ab (91.1% & 92.1% vs 88.4% & 88.4%) upon 14 days after booster vaccination, GMT in ReCOV group was higher than mRNA vaccine
- The neutralizing Ab induced by the ReCOV group increased by 30.8 & 27.3 times over baseline higher than the mRNA vaccine. In the ReCOV group, the neutralizing Ab was 2.5 & 2.6 times lower than the original strain which showed an excellent cross-neutralization effect
Ref: PRNewswire | Image:
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.